SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function
N Hansen, H Agerstam, M Wahlestedt, N Landberg, M Askmyr, M Ehinger, M Rissler, H Lilljebjorn, P Johnels, J Ishiko, JV Melo, WS Alexander, D Bryder, M Jaras, T Fioretos
Leukemia | NATURE PUBLISHING GROUP | Published : 2013
Awarded by Australian National Health and Medical Research Council
We wish to thank Dr. Jonas Larsson and Dr. Johan Richter for valuable discussions and Dr. Tor Olofsson for support and advice on cell sorting. Dr. Kavitha Siva is thanked for sharing her experiences of the CML mouse model. We are also grateful for the technical assistance from Carin Lassen. This work was supported by the Swedish Cancer Society, the Swedish Children's Cancer Foundation, the Inga-Britt and Arne Lundberg Foundation, the Gunnar Nilsson Cancer Foundation, the Medical Faculty of Lund University, and the Swedish Research Council (personal project grant to TF; Hemato-Linne and BioCare strategic program grants), a Program Grant (461219), Fellowship and Independent Research Institutes Infrastructure Support Scheme Grant from the Australian National Health and Medical Research Council, a Victorian State Government Operational Infrastructure Support grant (to WSA) and the NIHR Biomedical Research Center (UK) funding scheme.